Literature DB >> 17962610

Activation of growth factor receptors in esophageal cancer--implications for therapy.

Simon Ekman1, Michael Bergqvist, Carl-Henrik Heldin, Johan Lennartsson.   

Abstract

Esophageal cancer is a highly aggressive disease and is the seventh most common cause of cancer-related death in the western world. Worldwide, it ranks as the sixth most frequent cause of cancer death. Despite advances in surgical techniques and treatment, the prognosis of esophageal cancer remains poor, with very few long-term survivors. The need for novel strategies to detect esophageal cancer earlier and to improve current therapy is urgent. It is well established that growth factors and growth factor receptor-mediated signaling pathways are important components of the transformation process in many forms of cancer, including esophageal cancer. With the recent advances in drug development, there are emerging possibilities to use growth factor signal transduction pathways in targeted therapy. This review provides a summary of the role of growth factors and their receptors in esophageal cancer and discusses their potential roles as biomarkers and as targets in therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962610     DOI: 10.1634/theoncologist.12-10-1165

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  12 in total

1.  The status of phosphorylated p38 in esophageal squamous cell carcinoma.

Authors:  Shu-Tao Zheng; Chuan-Shan Zhang; Xu Qin; Yue-Hua Gen; Tao Liu; Ilyar Sheyhidin; Xiao-Mei Lu
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

2.  A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.

Authors:  David J Adelstein; Cristina P Rodriguez; Lisa A Rybicki; Denise I Ives; Thomas W Rice
Journal:  Invest New Drugs       Date:  2011-08-24       Impact factor: 3.850

3.  Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.

Authors:  Sabitha Papineni; Sudhakar Chintharlapalli; Maen Abdelrahim; Syng-ook Lee; Robert Burghardt; Ala Abudayyeh; Cheryl Baker; Luis Herrera; Stephen Safe
Journal:  Carcinogenesis       Date:  2009-04-30       Impact factor: 4.944

4.  Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC).

Authors:  Chi Hang Wong; Brigette Buig Yue Ma; Connie Wun Chun Hui; Qian Tao; Anthony Tak Cheung Chan
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

5.  Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.

Authors:  Cathy B Moelans; Paul J van Diest; Anya N A Milne; G Johan A Offerhaus
Journal:  Patholog Res Int       Date:  2010-12-06

6.  Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods.

Authors:  Jian Zhang; Jeremiah Bowers; Lingyan Liu; Siwei Wei; G A Nagana Gowda; Zane Hammoud; Daniel Raftery
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

7.  ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.

Authors:  Eva A Ebbing; Jan Paul Medema; Helene Damhofer; Sybren L Meijer; Kausilia K Krishnadath; Mark I van Berge Henegouwen; Maarten F Bijlsma; Hanneke W M van Laarhoven
Journal:  Oncotarget       Date:  2016-03-01

Review 8.  The tumor microenvironment in esophageal cancer.

Authors:  E W Lin; T A Karakasheva; P D Hicks; A J Bass; A K Rustgi
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

9.  Genetic polymorphisms of ATG5 predict survival and recurrence in patients with early-stage esophageal squamous cell carcinoma.

Authors:  Pei-Wen Yang; Min-Shu Hsieh; Ya-Han Chang; Pei-Ming Huang; Jang-Ming Lee
Journal:  Oncotarget       Date:  2017-09-08

10.  1H-NMR based metabonomic profiling of human esophageal cancer tissue.

Authors:  Liang Wang; Jie Chen; Longqi Chen; Pengchi Deng; Qian Bu; Pu Xiang; Manli Li; Wenjie Lu; Youzhi Xu; Hongjun Lin; Tianming Wu; Huijuan Wang; Jing Hu; Xiaoni Shao; Xiaobo Cen; Ying-Lan Zhao
Journal:  Mol Cancer       Date:  2013-04-04       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.